(Boursier.com) — Neovacs raised funds of 2 ME by drawing 2 tranches of OCEANE-BSA, with a nominal value of 1 ME, subscribed by European High Growth Opportunities Securitization Fund.
50% of the net proceeds from this operation (€1.92 million) will be used to finance the Kinoid research program on allergies and 50% to build investment capacity in promising projects, both in the development of drug candidates (BioTech) and medical devices (MedTech).
“This activity, which has resulted in two equity investments to date (Bio Detection K9 and Signia Therapeutics) will diversify the risk carried by Neovacs by investing in ambitious but realistic projects”, writes Neovacs.
©2022 Boursier.com